HRP20100104T1 - Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide - Google Patents
Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide Download PDFInfo
- Publication number
- HRP20100104T1 HRP20100104T1 HR20100104T HRP20100104T HRP20100104T1 HR P20100104 T1 HRP20100104 T1 HR P20100104T1 HR 20100104 T HR20100104 T HR 20100104T HR P20100104 T HRP20100104 T HR P20100104T HR P20100104 T1 HRP20100104 T1 HR P20100104T1
- Authority
- HR
- Croatia
- Prior art keywords
- corticosteroid
- simultaneous
- combination
- combination according
- treatment
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title claims 12
- 239000003149 muscarinic antagonist Substances 0.000 title claims 6
- 229960001334 corticosteroids Drugs 0.000 title claims 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims abstract 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims abstract 4
- 150000001450 anions Chemical class 0.000 claims abstract 4
- 239000005557 antagonist Substances 0.000 claims abstract 4
- 239000002253 acid Substances 0.000 claims abstract 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract 3
- ZLLPOXZGRDWOKF-LBFFRULKSA-N [(3R)-1-(1-phenylethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9H-xanthene-9-carboxylate Chemical compound C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12C(C)C1=CC=CC=C1 ZLLPOXZGRDWOKF-LBFFRULKSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims 6
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 5
- 208000023504 respiratory system disease Diseases 0.000 claims 5
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 229960004436 budesonide Drugs 0.000 claims 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 2
- 229940124748 beta 2 agonist Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- 102100037346 Substance-P receptor Human genes 0.000 claims 1
- UWBJXLMHPBMEJX-ZXKIDFLWSA-M [(3R)-1-(1-phenylethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9H-xanthene-9-carboxylate bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12C(C)C1=CC=CC=C1 UWBJXLMHPBMEJX-ZXKIDFLWSA-M 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Kombinacija, naznačena time, da sadrži (a) kortikosteroid i (b) antagonist M3 muskarinskih receptora koji je (3R)-1-feniletil-3-(9H-ksanten-9-karboniloksi)-1-azoniabiciklo[2.2.2]oktan, u obliku soli koji ima anion X, koji je farmaceutski prihvatljivi anion jedno ili više valentne kiseline. Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Kombinacija, naznačena time, da sadrži (a) kortikosteroid i (b) antagonist M3 muskarinskih receptora koji je (3R)-1-feniletil-3-(9H-ksanten-9-karboniloksi)-1-azoniabiciklo[2.2.2]oktan, u obliku soli koji ima anion X, koji je farmaceutski prihvatljivi anion jedno ili više valentne kiseline.
2. Kombinacija u skladu s patentnim zahtjevom 1, naznačena time, da antagonist M3 muskarinskog receptora (b) jeste (3R)-1-feniletil-3-(9H-ksanten-9-karboniloksi)-1 -azoniabiciklo[2.2.2]oktan bromid.
3. Kombinacija u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je kortikosteroid odabran iz skupine koja se sastoji od deksametazona, budesonida, beklometazona, triamcinolona, mometazona, ciklesonida, flutikasona, flunisolida, deksametazon natrij fosfata i njihovih estera kao i 6α9β-difluoro-17α-[2-furanilkarbonil)oksi]-11β-hidroksi-16α-metil-3-oksoandrosta-1,4-dien-17β-(S)-fluorometil ester karbotio kiseline.
4. Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je kortikosteroid odabran iz skupine koja sadrži budesonid i beklometazon dipropionat.
5. Kombinacija u skladu s patentnim zahtjevom 4, naznačena time, da je kortikosteroid budesonid.
6. Kombinacija u skladu s patentnim zahtjevom 4, naznačena time, da je kortikosteroid beklometazon dipropionat.
7. Kombinacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da djelatne tvari (a) i (b) tvore dio jednog farmaceutskog pripravka.
8. Kombinacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da nadalje sadrži (c) drugu djelatnu tvar odabranu od: (a) inhibitora PDE IV, (b) β2 agonista, (c) antagonista D4 leukotriena, (d) inhibitora egfr-kinaze, (e) inhibitora p38 kinaze i (f) NK1 agoniste receptora.
9. Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatna tvar (c) odabrana iz skupine koja se sastoji od (a) inhibitora PDE IV i (b) β2 agonista.
10. Uporaba (a) kortikosteroida kako je definirano u bilo kojem od patentnih zahtjeva 1 i 3 do 6 i (b) antagonist M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2, naznačena time, da je za pripravu lijeka za istovremenu, istodobnu, odijeljenu ili uzastopnu uporabu u liječenju dišnih bolesti koji odgovaraju M3 antagonizmu u ljudi ili životinja.
11. Uporaba u skladu s patentnim zahtjevom 10, naznačen time, da je plućna bolest astma ili kronična opstruktivna plućna bolest (COPD).
12. Proizvod, naznačen time, da sadrži (a) kortikosteroid kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 6 i (b) antagonist M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2, kao kombinirani pripravak za istovremenu, istodobnu, odijeljenu ili uzastopnu uporabu u liječenju pacijenata koji pate ili su podložni bolestima dišnih putova kako je definirano u patentnom zahtjevu 10 ili 11.
13. Proizvod u skladu s patentnim zahtjevom 12, naznačen time, da nadalje sadrži djelatnu tvar (c), kako je definirana u patentnom zahtjevu 8 ili 9.
14. Pribor, naznačen time, da se sastoji od (b) antagonista M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2 zajedno s uputama za istovremenu, istodobnu, odijeljenu ili uzastopnu uporabu u kombinaciji s (a) kortikosteroidom kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 6 za liječenje ljudskih i životinjskih pacijenata koji pate ili su podložni dišnim bolestima kako su definirane u patentnom zahtjevu 10 ili 11.
15. Pribor u skladu s patentnim zahtjevom 14, naznačen time, da dalje sadrži djelatnu tvar (c), kako je definirano u patentnom zahtjevu 8 ili 9.
16. Pakiranje, naznačeno time, da se sastoji od (b) antagonista M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2 i (a) kortikosteroida kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 6 za istovremenu, istodobnu, odijeljenu i uzastopnu uporabu za liječenje ljudi i životinja koji pate ili su podložni dišnim bolestima kako je definirano u patentnom zahtjevu 10 ili 11.
17. Pakiranje u skladu s patentnim zahtjevom 16, naznačen time, da dalje sadrži djelatnu tvar (c), kako je definirana u patentnom zahtjevu 8 ili 9.
18. Uporaba (b) antagonista M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2, naznačena time, da je za uporabu u kombinaciji s (a) kortikosteroidom kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 6 za liječenje dišnih bolesti kako su definirane u patentnom zahtjevu 10 ili 11.
19. Uporaba (a) kortikosteroida kako je definirano u patentnim zahtjevima 1 i 3 do 6, naznačena time, da je za pripravu lijeka za istovremenu, istodobnu, odijeljenu ili uzastopnu uporabu u kombinaciji s (b) antagonistom M3 muskarinskih receptora kako su definirani u patentnom zahtjevu 1 ili 2 za liječenje dišnih bolesti kako su definirane u patentnom zahtjevu 10 ili 11.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200401312A ES2257152B1 (es) | 2004-05-31 | 2004-05-31 | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP2005001969 | 2005-02-24 | ||
| GB2005000722 | 2005-02-25 | ||
| GB2005000740 | 2005-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100104T1 true HRP20100104T1 (hr) | 2010-04-30 |
Family
ID=34968792
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090106T HRP20090106T3 (hr) | 2004-05-31 | 2009-02-20 | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergičke agoniste |
| HR20100104T HRP20100104T1 (hr) | 2004-05-31 | 2010-02-26 | Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide |
| HR20100490T HRP20100490T1 (hr) | 2004-05-31 | 2010-09-03 | Kombinacije koje sadrže antimuskarinska sredstva i pde4 inhibitore |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090106T HRP20090106T3 (hr) | 2004-05-31 | 2009-02-20 | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergičke agoniste |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100490T HRP20100490T1 (hr) | 2004-05-31 | 2010-09-03 | Kombinacije koje sadrže antimuskarinska sredstva i pde4 inhibitore |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20110224177A1 (hr) |
| EP (5) | EP1891974B1 (hr) |
| JP (1) | JP2012211183A (hr) |
| AT (3) | ATE474601T1 (hr) |
| AU (3) | AU2005247104B2 (hr) |
| CA (3) | CA2568571C (hr) |
| CY (1) | CY1110829T1 (hr) |
| DE (3) | DE602005018969D1 (hr) |
| DK (2) | DK1891974T3 (hr) |
| ES (2) | ES2317245T3 (hr) |
| HK (1) | HK1096605A1 (hr) |
| HR (3) | HRP20090106T3 (hr) |
| IL (3) | IL179685A (hr) |
| MX (3) | MXPA06013849A (hr) |
| NZ (3) | NZ551670A (hr) |
| PL (2) | PL1905451T3 (hr) |
| PT (3) | PT1905451E (hr) |
| RS (3) | RS51206B (hr) |
| RU (3) | RU2404772C2 (hr) |
| SI (3) | SI1765404T1 (hr) |
| WO (3) | WO2005115465A1 (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| WO2006085689A1 (ja) * | 2005-02-10 | 2006-08-17 | Oncolys Biopharma, Inc. | テロメライシン併用抗癌剤 |
| MX2009008794A (es) * | 2007-02-19 | 2009-08-25 | Cipla Ltd | Combinaciones farmaceuticas al menos de dos broncodilatadores o de un broncodilatador con un corticosteroide. |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| EP2080508A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| GB0811100D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination |
| GB0814728D0 (en) * | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| EP2400950B1 (en) | 2009-02-26 | 2019-05-22 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| WO2010097114A1 (en) * | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Novel combination of therapeutic agents |
| CN107722036B (zh) | 2009-05-14 | 2020-09-04 | 天津合美医药科技有限公司 | 噻吩衍生物 |
| GB0921075D0 (en) * | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| EP2836204B1 (en) | 2012-04-13 | 2020-07-08 | GlaxoSmithKline Intellectual Property Development Limited | Aggregate particles |
| GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
| EP2968313B1 (en) * | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| GB201308933D0 (en) * | 2013-05-17 | 2013-07-03 | Diurnal Ltd | Paediatric composition |
| CA2917320C (en) * | 2013-07-05 | 2020-10-13 | Bioneer Corporation | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, composition containing same for preventing or treating respiratory disease |
| TW201542207A (zh) * | 2013-10-03 | 2015-11-16 | Otsuka Pharma Co Ltd | 嚴重氣喘治療劑 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
| DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
| DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
| IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
| US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
| DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
| EP0640354B1 (en) | 1990-09-26 | 2001-12-05 | Pharmachemie B.V. | Whirl chamber powder inhaler |
| GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
| MY115140A (en) | 1992-12-18 | 2003-04-30 | Schering Corp | Inhaler for powdered medications |
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| BR9604977A (pt) | 1995-04-14 | 1998-06-09 | Glaxo Wellcome Inc | Inalador de dose medida sistema inalador de dose medida e uso do mesmo |
| HU220227B (hu) | 1995-06-21 | 2001-11-28 | Asta Medica A.G. | Gyógyszerporos patron integrált adagolószerkezettel és inhalálókészülék poralakú gyógyszerekhez |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| GB0009592D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
| GB0009605D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
| GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| GB0009606D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
| EP1318973A2 (en) * | 2000-09-22 | 2003-06-18 | Glaxo Group Limited | Novel alkanoic acid derivatives |
| WO2002036106A2 (de) | 2000-10-31 | 2002-05-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden |
| DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| DE10056104A1 (de) * | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
| CN1250545C (zh) * | 2000-12-28 | 2006-04-12 | 阿尔米雷尔普罗迪斯制药有限公司 | 新的奎宁环衍生物类及含有这类衍生物的药物组合物 |
| ATE347361T1 (de) * | 2001-05-25 | 2006-12-15 | Boehringer Ingelheim Pharma | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen |
| DE10130371A1 (de) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| ES2206021B1 (es) * | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| CA2519682A1 (en) * | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| CA2519679C (en) * | 2003-03-28 | 2012-08-28 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
-
2005
- 2005-05-31 CA CA2568571A patent/CA2568571C/en not_active Expired - Fee Related
- 2005-05-31 RS RSP-2010/0104A patent/RS51206B/sr unknown
- 2005-05-31 EP EP07019646A patent/EP1891974B1/en active Active
- 2005-05-31 NZ NZ551670A patent/NZ551670A/en not_active IP Right Cessation
- 2005-05-31 EP EP05746222A patent/EP1761279A1/en not_active Withdrawn
- 2005-05-31 EP EP10003385A patent/EP2210614A1/en not_active Withdrawn
- 2005-05-31 SI SI200530599T patent/SI1765404T1/sl unknown
- 2005-05-31 DE DE602005018969T patent/DE602005018969D1/de active Active
- 2005-05-31 RU RU2006147269/15A patent/RU2404772C2/ru not_active IP Right Cessation
- 2005-05-31 RS RSP-2010/0379A patent/RS51422B/en unknown
- 2005-05-31 RU RU2006146813/15A patent/RU2385156C2/ru not_active IP Right Cessation
- 2005-05-31 ES ES05748688T patent/ES2317245T3/es active Active
- 2005-05-31 DE DE602005022499T patent/DE602005022499D1/de active Active
- 2005-05-31 AT AT07019646T patent/ATE474601T1/de active
- 2005-05-31 ES ES07023760T patent/ES2336144T3/es active Active
- 2005-05-31 NZ NZ551669A patent/NZ551669A/en not_active IP Right Cessation
- 2005-05-31 PT PT07023760T patent/PT1905451E/pt unknown
- 2005-05-31 CA CA2569074A patent/CA2569074C/en not_active Expired - Fee Related
- 2005-05-31 AU AU2005247104A patent/AU2005247104B2/en not_active Ceased
- 2005-05-31 WO PCT/EP2005/005839 patent/WO2005115465A1/en not_active Application Discontinuation
- 2005-05-31 SI SI200530959T patent/SI1905451T1/sl unknown
- 2005-05-31 EP EP05759006A patent/EP1765405A1/en not_active Withdrawn
- 2005-05-31 WO PCT/EP2005/005837 patent/WO2005115463A1/en active Application Filing
- 2005-05-31 WO PCT/EP2005/005838 patent/WO2005115464A1/en not_active Application Discontinuation
- 2005-05-31 AU AU2005247106A patent/AU2005247106B2/en not_active Ceased
- 2005-05-31 PT PT07019646T patent/PT1891974E/pt unknown
- 2005-05-31 AT AT07023760T patent/ATE454904T1/de active
- 2005-05-31 MX MXPA06013849A patent/MXPA06013849A/es active IP Right Grant
- 2005-05-31 PL PL07023760T patent/PL1905451T3/pl unknown
- 2005-05-31 EP EP07023760A patent/EP1905451B1/en active Active
- 2005-05-31 RU RU2006146673/15A patent/RU2379033C2/ru not_active IP Right Cessation
- 2005-05-31 DE DE602005012102T patent/DE602005012102D1/de active Active
- 2005-05-31 AU AU2005247105A patent/AU2005247105B2/en not_active Ceased
- 2005-05-31 AT AT05748688T patent/ATE419011T1/de active
- 2005-05-31 CA CA2568568A patent/CA2568568C/en not_active Expired - Fee Related
- 2005-05-31 MX MXPA06013846A patent/MXPA06013846A/es active IP Right Grant
- 2005-05-31 RS RSP-2009/0075A patent/RS50786B/sr unknown
- 2005-05-31 MX MXPA06013850A patent/MXPA06013850A/es active IP Right Grant
- 2005-05-31 DK DK07019646.4T patent/DK1891974T3/da active
- 2005-05-31 PT PT05748688T patent/PT1765404E/pt unknown
- 2005-05-31 DK DK07023760.7T patent/DK1905451T3/da active
- 2005-05-31 SI SI200531128T patent/SI1891974T1/sl unknown
- 2005-05-31 NZ NZ551666A patent/NZ551666A/en not_active IP Right Cessation
- 2005-05-31 PL PL07019646T patent/PL1891974T3/pl unknown
-
2006
- 2006-11-29 IL IL179685A patent/IL179685A/en not_active IP Right Cessation
- 2006-11-29 IL IL179686A patent/IL179686A0/en unknown
- 2006-11-29 IL IL179690A patent/IL179690A/en not_active IP Right Cessation
-
2007
- 2007-04-03 HK HK07103580.3A patent/HK1096605A1/xx not_active IP Right Cessation
-
2009
- 2009-02-20 HR HR20090106T patent/HRP20090106T3/hr unknown
-
2010
- 2010-02-26 HR HR20100104T patent/HRP20100104T1/hr unknown
- 2010-09-03 HR HR20100490T patent/HRP20100490T1/hr unknown
- 2010-10-11 CY CY20101100905T patent/CY1110829T1/el unknown
-
2011
- 2011-03-14 US US13/047,039 patent/US20110224177A1/en not_active Abandoned
-
2012
- 2012-07-06 JP JP2012152730A patent/JP2012211183A/ja active Pending
- 2012-09-05 US US13/603,985 patent/US20130196961A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100104T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide | |
| CA2569077A1 (en) | Combinations comprising antimuscarinic agents and corticosteroids | |
| JP2008500990A5 (hr) | ||
| JP2008500988A5 (hr) | ||
| JP2008500986A5 (hr) | ||
| JP6501774B2 (ja) | Ｍａｂａ化合物およびコルチコステロイドを含む組合せ剤 | |
| JP2007520508A5 (hr) | ||
| JP2016510012A5 (hr) | ||
| US20160015704A1 (en) | Combinations comprising maba compounds and corticosteroids | |
| KR20140041699A (ko) | 우메클리디늄 및 코르티코스테로이드를 포함하는 조합물 | |
| US20160263091A1 (en) | Aclidinium for use in improving the quality of sleep in respiratory patients | |
| KR20180118667A (ko) | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 | |
| HRP20140818T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| KR20180119597A (ko) | 염증 상태의 급성 악화의 치료를 위한 투약법 | |
| KR20150096400A (ko) | 아클리디늄의 신규한 용도 | |
| KR20230052903A (ko) | 흡입 투여를 위한 병용 요법 | |
| US20190269703A1 (en) | Materials and methods for treating chronic cough | |
| KR20070018103A (ko) | 항무스카린제 및 코르티코스테로이드를 포함하는 조합물 | |
| KR20070017542A (ko) | 항무스카린제 및 ｐｄｅ4 저해제를 포함하는 조합물 | |
| KR20070017543A (ko) | 항무스카린제 및 ｐｄｅ4 저해제를 포함하는 조합물 |